UCLA Hematology/Oncology-San Luis Obispo

San Luis Obispo, California 93401

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Cancer of the Prostate, Early Breast Cancer, HER2 Positive Breast Cancer, HER2-positive Breast Cancer, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Prostate Cancer, Urothelial Carcinoma

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 — Running, not enrolling
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) — Completed